“Already this year, American communities have experienced floods, tornadoes and wildfires. Our country needs a better way to protect medically fragile people so natural disasters don’t become medical emergencies.
Thousands of people in the United States rely on electrically powered DME to meet their medical needs at home. While they can manage their medical conditions well on a day-to-day basis, in prolonged power outages, that’s when they need our help the most.
Each of us can make a difference during emergencies for people whose lives depend on electrical medical equipment. If you use electrically-powered medical equipment or care for someone who does, please take action today to be prepared for power outages.”
“My company is a prescription drug wholesale distributor (in-state or out-of-state). Our Certified Designated Representative (CDR) just quit. What do we do?
Notify the department within 10 business days from the CDR’s separation. Your company may continue to distribute prescription drugs in or into Florida during that 10-business day-period. After that period expires, however, your company must either (a) engage a replacement CDR and notify the department of same or (b) cease prescription drug distributions in or into Florida.
The Department can, upon written request to appropriate personnel, provide a list of all unaffiliated CDR’s.”
“In a shift from the current system, Medicare is proposing to rule on seniors’ coverage for home medical devices before the supplies are delivered or claims for payment are submitted. The Centers for Medicare and Medicaid Services CMS is planning to expand the use of “prior authorization” for power scooters and wheelchairs, and introduce the process for several other categories of medical goods used at home.
Officials said the effort is targeting improper payments and fraud in the system, when Medicare foots the bill for products aggressively marketed to patients and doctors who do not need them.”
How To Approach, Read, and Interpret the DSCSA
Another great educational snippet from Dirk Rodgers (RxTrace). Follow the link below to read his full article.
“So let’s apply that to the exchange of Transaction Information TI, Transaction History TI, and Transaction Statements TS that all U.S. pharma supply chain trading partners must do beginning on January 1 of next year (dispensers don’t have to do it until July 1 of next year) (see “DQSA: How Should Transaction Data Be Exchanged?”). First, the DSCSA that contains this requirement is a law, which means non-exempt trading partners are obligated to follow those requirements or be exposed to penalties.
The DSCSA also obligates the FDA to take certain actions on a particular schedule (see “Decoding The FDA’s DSCSA Timeline”). Two of those actions are the publication of guidance on identification of suspect product and termination of notifications of illegitimate product, which is due by next Monday, and the publication of draft guidance establishing standards for interoperable exchange of TI, TH and TS in paper or electronic format, which is due on or before November 27 of this year. Both of these are guidance, which means they will contain non-binding information that represents the current thinking of the FDA on those topics.” via The Differences Between The DSCSA, FDA Rules and Guidance.